Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02464332
Recruitment Status : Withdrawn (Study did not enroll any subjects)
First Posted : June 8, 2015
Last Update Posted : May 26, 2016
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Blaze Bioscience Inc.

Brief Summary:
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue, and failure to surgically remove a cancer-affected lymph node or residual cancer at the surgical margin reduces a patient's chance of survival. Moreover, damage to adjacent normal tissue during surgery can result in significant morbidity. The investigators hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as they operate. This is a safety study to assess the safety of BLZ-100 in patients with soft tissue sarcoma undergoing surgery.

Condition or disease Intervention/treatment Phase
Sarcoma, Soft Tissue Drug: BLZ-100 Phase 1

Detailed Description:

Subjects who provide voluntary written informed consent will be screened for eligibility. Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to participate.

This is a two part study:

Part 1 - Dose Finding: Subjects will be required to arrive at the phase 1 unit for dosing 2-3 days prior to the planned surgical excision. Two dose levels of BLZ-100 (3 mg and 12 mg) will be evaluated in a total of 6 subjects with a 2-3 day post-dose imaging interval (also defined as the Intermediate Imaging interval).

Part 2 - Imaging Interval Assessment: The BLZ-100 dose to be evaluated in Part 2 will be determined by the Protocol Steering Committee following completion of Part 1. In Part 2, up to 15 additional subjects will be randomized into one of three imaging interval groups (up to 6 subjects per group): Early Imaging (within 1 day post BLZ-100 dose), Intermediate Imaging (2-3 days post BLZ-100 dose), and Late Imaging (4-7 days post BLZ-100 dose). Subjects will be required to arrive at the phase 1 unit for dosing between 1 and 7 days prior to planned surgical excision, depending on which imaging interval they are randomized to.

Following dosing, all subjects will be monitored for safety.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A Phase 1 Study of BLZ-100 Administered by Intravenous Injection in Subjects With Soft Tissue Sarcoma Undergoing Surgery
Study Start Date : September 2015
Actual Primary Completion Date : May 2016
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: BLZ-100

All participants in the study will receive the investigational drug product BLZ-100.

In part 1 of the study, two dose levels of BLZ-100 will be evaluated (3 mg and 12 mg) in 6 subjects, with a 2-3 post-dose imaging window.

In part 2 of the study up to 15 additional subjects will be randomized to one of three imaging interval groups (up to 6 subjects/interval): Early Imaging (within 1 day post-BLZ-100 dose), Intermediate Imaging (2 - 3 days post- BLZ-100 dose), and Late Imaging (4 - 7 days post- BLZ-100 dose).

Drug: BLZ-100

All subjects enrolled in the study will receive doses of BLZ-100, an investigational drug for imaging tumors.

Three different imaging windows will be investigated during the study:

Early Imaging (imaging occurs within 1 day post-BLZ-100 dose); Intermediate Imaging (imaging occurs within 2-3 days post-BLZ-100 dose); Late Imaging (imaging occurs 4-7 post-BLZ-100 dose)

All subjects in Part 1 of the study will be imaged in the Intermediate Imaging group. Subjects in Part 2 of the study will be randomized into one of the three imaging groups.

Other Name: Tumor Paint

Primary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: Seven days after study drug administration ]
    Safety will be assessed by physical examination and measurement of vital signs and laboratory safety parameters.

Secondary Outcome Measures :
  1. Change of concentration of BLZ-100 in the blood [ Time Frame: Prior to dosing and at 1 minute, 5 minutes, 15 minutes, 30 minutes, 60 minutes and 120 minutes after end of injection, and pre-surgery and 24 hours post-surgery ]
    BLZ-100 levels in blood will be analyzed by chemical means and these data will be used to calculate pharmacokinetic parameters.

  2. Fluorescence signal from areas of tumor and non-tumor [ Time Frame: 1 day post-dose, 2-3 days post-dose, or 3-7 days post-dose ]
    Fluorescent signal in sections of excised tumor and adjacent normal tissue will be measured using an infrared imaging system.

  3. Ideal combination of dose and imaging interval [ Time Frame: 1 day post-dose, 2-3 days post-dose, 3-7 days post-dose ]
    Fluorescent signal will be evaluated in sections of excised tumor and adjacent normal tissue to determine which imaging interval provides the optimal images.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male of female subject aged 18-75 years
  2. Diagnosis of soft tissue sarcoma, with scheduled surgical removal for treatment for the disease and completion of chemotherapy or radiation within 4 weeks of BLZ-100 administration
  3. Able to provide written informed consent
  4. If of child-bearing potential, agree to continued use of two reliable methods of contraceptive from study entry (time of informed consent) through 30 days after BLZ-100 administration
  5. Available for all study visits and able to comply with all study requirements

Exclusion Criteria:

  1. Clinically-suspected and/or pathologically-confirmed sarcoma of the bone (e.g. osteosarcoma, Ewing's sarcoma with bony involvement, chondrosarcoma, Kaposi's sarcoma, extraosseous primitive neuroectodermal tumor [PNET])
  2. Evidence of metastatic disease
  3. Female who is lactating/breastfeeding
  4. Female with a positive pregnancy test or who is planning to become pregnant during the duration of the study
  5. Karnofsky Performance Status of <60%
  6. Any of the following laboratory abnormalities at Screening:

    • Neutrophil count <1.5 x 10^9/L
    • Platelets <75 x 10^9/L
    • Hemoglobin <10 g/dL (may be determined following transfusion)
    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3x upper limit of normal (ULN)
    • Total bilirubin >1.5x upper limit of reference range (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction)
    • Internal Normalized Ratio (INR) >1.5
    • Creatinine >1.5x ULN
    • Calculated estimated glomerular filtration rate (eGFR) ≤60 mL/min
  7. Positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)
  8. QTc prolongation >450 msec
  9. History of hypersensitivity or allergic reactions requiring corticosteroids, epinephrine, and/or hospitalization
  10. Uncontrolled asthma or asthma requiring oral corticosteroids
  11. Known or suspected sensitivity to imaging agents that may be used in clinical assessment of this study
  12. Known or suspected sensitivity to indocyanine green (ICG)
  13. Unstable angina, myocardial infarction, known or suspected transient ischemic events, or stroke within 24 weeks of start of Screening
  14. Uncontrolled hypertension
  15. Initiation of new photosensitizing drugs within 30 days of Screening
  16. Use of any ongoing medications, which might generate fluorescence or, according to the medication label, might generate a photochemical reaction. These include haematoporphyrin derivatives and purified fractions, Photofrin®, and the precursors of protoporphyrin IX (5-Aminolevulinic acid) used in Gliolan or Hexvix
  17. Receipt of an investigational drug or device within 30 days of enrollment
  18. Prior administration of BLZ-100
  19. Any concurrent condition, including psychological and social situations, which, in the opinion of the investigator, would adversely impact the subject or the interpretation of the study data

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02464332

United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Sponsors and Collaborators
Blaze Bioscience Inc.
National Cancer Institute (NCI)
Principal Investigator: Charles Forscher, MD Cedars-Sinai Medical Center

Responsible Party: Blaze Bioscience Inc. Identifier: NCT02464332     History of Changes
Other Study ID Numbers: BB-003
261201400046C-0-0-1 ( U.S. NIH Grant/Contract )
First Posted: June 8, 2015    Key Record Dates
Last Update Posted: May 26, 2016
Last Verified: May 2016

Keywords provided by Blaze Bioscience Inc.:
soft tissue sarcoma
Tumor Paint

Additional relevant MeSH terms:
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type